Contura Orthopaedics Ltd joins the International Cartilage Regeneration & Joint Preservation Society as its newest industry partner
Contura Orthopaedics Ltd. is delighted to join the International Cartilage Regeneration & Joint Preservation Society as its newest industry partner and sponsor of the ICRS Patient Registry - the first and only independent international database for monitoring the clinical outcomes of cartilage repair and joint preservation treatments.
This partnership aligns with the Registry’s mission to improve existing cartilage repair strategies and optimise patient outcomes through the analysis of clinical and patient-reported data. To mark the beginnings of this important collaboration, Contura’s minimally invasive treatment based on 97.5% water and 2.5% cross-linked polyacrylamide, “2.5 iPAAG”, for patients with knee osteoarthritis, Arthrosamid®, will feature in the ICRS Registry.
As part of this, clinicians will be encouraged to take advantage of the exciting opportunity to enrol eligible patients into the free and multi-lingual Registry. All ICRS Registry data is stored securely in line with GDPR guidelines, making it an ideal place for clinicians to keep track of their patients’ outcomes. Clinicians can also benefit from bespoke reporting functions, which can be used for annual performance reviews.
Rakesh Tailor, CEO of Contura International comments, “We’re so thrilled to have pioneered the 2.5 iPAAG technology behind Arthrosamid. It has the potential to revolutionise the treatment of musculo-skeletal disorders in both humans and animals. Joining the ICRS Patient Registry is important for patient outcomes with Arthrosamid to be independently recorded. As a non-surgical treatment, its impact on patients’ lives can be compared to conditions otherwise treated with more invasive surgery, such as knee replacements, which can be risky, requiring hospital stays and lengthy recovery periods for patients.”
The ICRS brings together a community of scientists, clinical researchers, physicians, healthcare providers and industry experts. Arthrosamid® expects to be a valuable contributor to this group, partnering to offer educational resources, access to research, meetings and skills courses.
Being part of the Registry means that Arthrosamid® will help to monitor the progress of patients who have been diagnosed with knee osteoarthritis. The response of patients can be variable. Therefore, it is vital that patient progress is monitored, particularly in order to ensure treatments at the forefront of medical advances are cost-effective and of value to patient quality of life.
Registry members can monitor their own patients’ progress through the Registry, having direct access to their own data. To monitor the progress of patients for all recorded treatments within the Registry, the ICRS are able to analyse and assess which techniques are working best for which patients. Ultimately, the data held by this Registry will help future patients with similar injuries and rapidly identify treatments that are showing great benefit, as well as those that may not be performing as well as hoped. This helps the Registry to perform cost-effectiveness and health economic analyses of the data in future.
Mr. Mike McNicholas, Chairman of the ICRS registry comments,
As the Chair of the ICRS Registry Steering Committee, it gives me great pleasure to welcome Contura as a Gold Level sponsor of the Registry. The Registry is already in use across 50 countries in 13 languages and includes data from 3,500 patients. If you would like to know more, please visit cartilage.org/society/icrs-patient-registry/.
Contura has a novel intra-articular injectable for the treatment of painful knee osteoarthritis, and their involvement with the ICRS Registry to support the independent collection of patient outcomes reflects the company’s longstanding tradition of responsibly introducing products, like Arthrosamid, to market.
Their long-term commitment will allow us to continue our valuable work where the aim is to be the best source of information for patients and for our ourselves, as scientists and clinicians, working to help those unfortunate enough to suffer the pain and disability associated with osteoarthritis.
Their generous support will allow both our organisations to achieve our mutual goals in helping our patients gain comfort and improve their quality of life.”
The Registry was established in 2016 at the ICRS Meeting in Italy and is guided by a Steering Committee comprised of orthopaedic surgeons, equine surgeons, clinician scientists, and research scientists.